ResMed – Opportunity Approaches

ResMed is a current holding in our ASX 100 model portfolio.

The company reports 1Q20 earnings on 25 October and we expect revenue growth to be 15%+ and EBIT to be up 10%+ on the same time last year.

You’re not a member!  Trial today

We look for an entry-level into RMD on the current price weakness and will update our readers further, following the earnings result.

 

 

Ready to elevate your investing?

Join Investor Signals today and start your journey to better, more disciplined returns.